Skip to main content
Top
Published in: BMC Medical Genetics 1/2017

Open Access 01-12-2017 | Case report

Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD)

Authors: N. C. Ramchander, N. A. J. Ryan, E. J. Crosbie, D. G. Evans

Published in: BMC Medical Genetics | Issue 1/2017

Login to get access

Abstract

Background

Constitutional mismatch repair deficiency syndrome results from bi-allelic inheritance of mutations affecting the key DNA mismatch repair genes: MLH1, MSH2, MSH6 or PMS2. Individuals with bi-allelic mutations have a dysfunctional mismatch repair system from birth; as a result, constitutional mismatch repair deficiency syndrome is characterised by early onset malignancies. Fewer than 150 cases have been reported in the literature over the past 20 years. This is the first report of the founder PMS2 mutation - NM_000535.5:c.1500del (p.Val501TrpfsTer94) in exon 11 and its associated cancers in this family.

Case presentation

The proband is 30 years old and is alive today. She is of Pakistani ethnic origin and a product of consanguinity. She initially presented aged 24 with painless bleeding per-rectum from colorectal polyps and was referred to clinical genetics. Clinical examination revealed two café-au-lait lesions, lichen planus, and a dermoid cyst. Her sister had been diagnosed in childhood with an aggressive brain tumour followed by colorectal cancer. During follow up, the proband developed 37 colorectal adenomatous polyps, synchronous ovarian and endometrial adenocarcinomas, and ultimately a metachronous gastric adenocarcinoma. DNA sequencing of peripheral lymphocytes revealed a bi-allelic inheritance of the PMS2 mutation NM_000535.5:c.1500del (p.Val501TrpfsTer94) in exon 11. Ovarian tumour tissue demonstrated low microsatellite instability. To date, she has had a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and a total gastrectomy. Aspirin and oestrogen-only hormone replacement therapy provide some chemoprophylaxis and manage postmenopausal symptoms, respectively. An 18-monthly colonoscopy surveillance programme has led to the excision of three high-grade dysplastic colorectal tubular adenomatous polyps. The proband’s family pedigree displays multiple relatives with cancers including a likely case of ‘true’ Turcot syndrome.

Conclusions

Constitutional mismatch repair deficiency syndrome should be considered in patients who present with early onset cancer, a strong family history of cancer, and cutaneous features resembling neurofibromatosis type I. Immunohistochemistry analysis of tumour and normal tissue is sensitive and specific for identifying patients with mismatch repair deficiency and should direct DNA sequencing of lymphocytic tissue to establish a diagnosis. Microsatellite instability status appears to be of little value in identifying patients who may have constitutional mismatch repair deficiency syndrome.
Literature
1.
go back to reference Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999;9(1):89–96.CrossRefPubMed Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999;9(1):89–96.CrossRefPubMed
3.
go back to reference Warthin AS. Heredity With Reference To Carcinoma: As Shown By the Study of the Cases Examined in the Pathological Laboratory of the University of Michigan, 1895-1913. Arch Intern Med. 1913;12(5):546–55.CrossRef Warthin AS. Heredity With Reference To Carcinoma: As Shown By the Study of the Cases Examined in the Pathological Laboratory of the University of Michigan, 1895-1913. Arch Intern Med. 1913;12(5):546–55.CrossRef
4.
go back to reference Douglas JA, Gruber SB, Meister KA, Bonner J, Watson P, Krush AJ, et al. History and molecular genetics of Lynch syndrome in family G: a century later. JAMA. 2005;294(17):2195–202.CrossRefPubMed Douglas JA, Gruber SB, Meister KA, Bonner J, Watson P, Krush AJ, et al. History and molecular genetics of Lynch syndrome in family G: a century later. JAMA. 2005;294(17):2195–202.CrossRefPubMed
6.
go back to reference Lynch HT, Hitchins MP, Shaw TG, Lynch JF, Roy H. Hereditary Colorectal Cancer. Arch Intern Med. 2010;348(10):15–43. Lynch HT, Hitchins MP, Shaw TG, Lynch JF, Roy H. Hereditary Colorectal Cancer. Arch Intern Med. 2010;348(10):15–43.
7.
go back to reference Ricciardone MD, Ozçelik T, Cevher B, Ozdağ H, Tuncer M, Gürgey A, et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res. 1999;59(2):290–3.PubMed Ricciardone MD, Ozçelik T, Cevher B, Ozdağ H, Tuncer M, Gürgey A, et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res. 1999;59(2):290–3.PubMed
8.
go back to reference Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. Eur J Cancer. 2014;50(5):987–96.CrossRefPubMed Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. Eur J Cancer. 2014;50(5):987–96.CrossRefPubMed
9.
go back to reference Vasen HF, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet. 2014;51(5):283–93.CrossRefPubMed Vasen HF, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet. 2014;51(5):283–93.CrossRefPubMed
10.
go back to reference Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium “care for CMMRD” (C4CMMRD). J Med Genet. 2014;51(6):355–65.CrossRefPubMed Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium “care for CMMRD” (C4CMMRD). J Med Genet. 2014;51(6):355–65.CrossRefPubMed
11.
go back to reference Durno CA, Sherman PM, Aronson M, Malkin D, Hawkins C, Bakry D, et al. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. Eur J Cancer. 2015;51(8):977–83.CrossRefPubMed Durno CA, Sherman PM, Aronson M, Malkin D, Hawkins C, Bakry D, et al. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. Eur J Cancer. 2015;51(8):977–83.CrossRefPubMed
12.
go back to reference Hendriks YMC, Jagmohan-Changur S, Van Der Klift HM, Morreau H, Van Puijenbroek M, Tops C, et al. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology. 2006;130(2):312–22.CrossRefPubMed Hendriks YMC, Jagmohan-Changur S, Van Der Klift HM, Morreau H, Van Puijenbroek M, Tops C, et al. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology. 2006;130(2):312–22.CrossRefPubMed
13.
go back to reference Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.CrossRefPubMedPubMedCentral Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.CrossRefPubMedPubMedCentral
15.
go back to reference Gallinger S, Aronson M, Shayan K, Ratcliffe EM, Gerstle JT, Parkin PC, et al. Gastrointestinal Cancers and Neurofibromatosis Type 1 Features in Children with a Germline Homozygous MLH1 Mutation. Gastroenterology. 2004;126(2):576–85.CrossRefPubMed Gallinger S, Aronson M, Shayan K, Ratcliffe EM, Gerstle JT, Parkin PC, et al. Gastrointestinal Cancers and Neurofibromatosis Type 1 Features in Children with a Germline Homozygous MLH1 Mutation. Gastroenterology. 2004;126(2):576–85.CrossRefPubMed
16.
go back to reference De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet. 2004;74(5):954–64.CrossRefPubMedPubMedCentral De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet. 2004;74(5):954–64.CrossRefPubMedPubMedCentral
17.
go back to reference Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: Have we so far seen only the tip of an iceberg? Hum Genet. 2008;124(2):105–22.CrossRefPubMed Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: Have we so far seen only the tip of an iceberg? Hum Genet. 2008;124(2):105–22.CrossRefPubMed
18.
go back to reference Turcot J, Després J, Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon. Dis Colon Rectum. 1959;2(5):465–8.CrossRefPubMed Turcot J, Després J, Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon. Dis Colon Rectum. 1959;2(5):465–8.CrossRefPubMed
20.
go back to reference Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome: Two genetic diseases? J Clin Oncol. 1997;15(7):2744–58.CrossRefPubMed Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome: Two genetic diseases? J Clin Oncol. 1997;15(7):2744–58.CrossRefPubMed
22.
go back to reference Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al. The Molecular Basis of Turcot’s Syndrome. N Engl J Med. 1995;332(13):839–47.CrossRefPubMed Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al. The Molecular Basis of Turcot’s Syndrome. N Engl J Med. 1995;332(13):839–47.CrossRefPubMed
23.
go back to reference Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999;117(1):123–31.CrossRefPubMedPubMedCentral Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999;117(1):123–31.CrossRefPubMedPubMedCentral
24.
go back to reference Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007;44(6):353–62.CrossRefPubMedPubMedCentral Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007;44(6):353–62.CrossRefPubMedPubMedCentral
25.
go back to reference Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66(8):3987–91.CrossRefPubMed Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66(8):3987–91.CrossRefPubMed
26.
go back to reference Burn J, Gerdes AM, MacRae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7.CrossRefPubMedPubMedCentral Burn J, Gerdes AM, MacRae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7.CrossRefPubMedPubMedCentral
27.
go back to reference McIlhatton MA, Tyler J, Burkholder S, Ruschoff J, Rigas B, Kopelovich L, et al. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res. 2007;67(22):10966–75.CrossRefPubMed McIlhatton MA, Tyler J, Burkholder S, Ruschoff J, Rigas B, Kopelovich L, et al. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res. 2007;67(22):10966–75.CrossRefPubMed
28.
go back to reference Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829–34.CrossRefPubMed Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829–34.CrossRefPubMed
29.
go back to reference Rondagh EJA, Gulikers S, Gómez-García EB, Vanlingen Y, Detisch Y, Winkens B, et al. Nonpolypoid colorectal neoplasms: A challenge in endoscopic surveillance of patients with Lynch syndrome. Endoscopy. 2013;45(4):257–64.CrossRefPubMed Rondagh EJA, Gulikers S, Gómez-García EB, Vanlingen Y, Detisch Y, Winkens B, et al. Nonpolypoid colorectal neoplasms: A challenge in endoscopic surveillance of patients with Lynch syndrome. Endoscopy. 2013;45(4):257–64.CrossRefPubMed
30.
go back to reference Niv Y, Moeslein G, Vasen HF, Karner-Hanusch J, Lubinsky J, Gasche C, et al. Quality of colonoscopy in Lynch syndrome. Endosc Int open. 2014;2(4):252–5.CrossRef Niv Y, Moeslein G, Vasen HF, Karner-Hanusch J, Lubinsky J, Gasche C, et al. Quality of colonoscopy in Lynch syndrome. Endosc Int open. 2014;2(4):252–5.CrossRef
31.
go back to reference Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812–23.CrossRefPubMedPubMedCentral Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812–23.CrossRefPubMedPubMedCentral
32.
go back to reference Watson M, Lloyd S, Davidson J, Meyer L, Eeles R, Ebbs S, et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer. 1999;79(5–6):868–74.CrossRefPubMedPubMedCentral Watson M, Lloyd S, Davidson J, Meyer L, Eeles R, Ebbs S, et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer. 1999;79(5–6):868–74.CrossRefPubMedPubMedCentral
Metadata
Title
Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD)
Authors
N. C. Ramchander
N. A. J. Ryan
E. J. Crosbie
D. G. Evans
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2017
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-017-0391-x

Other articles of this Issue 1/2017

BMC Medical Genetics 1/2017 Go to the issue